Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,233–1,240 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
CDT Equity Inc. AZD1656 Renal Transplant Phase 2 Trial Planned oral Immunosuppressant
CDT Equity Inc. AZD1656 Hashimoto’s Thyroiditis Phase 2 Trial Planned oral Endocrinology
CDT Equity Inc. AZD1656 Uveitis Phase 2 Trial Planned oral Opthalmic
CDT Equity Inc. AZD1656 Preterm Labor Phase 2 Trial Planned oral Women's Health
Celcuity Inc. VIZIMPRO (dacomitinib) and XALKORI (crizotinib) - (FACT-3) HER2-negative breast cancer Phase 2 Trial Discontinued Oral Oncology
Celcuity Inc. NERLYNX (neratinib) and Xeloda (capecitabine) HER2-negative breast cancer Phase 2 Trial Planned Oral Oncology
Celcuity Inc. TABRECTA (capmatinib) and NERLYNX (Neratinib) - (FACT-5) HER2-negative breast cancer Phase 2 Trial Planned Oral Oncology
Celcuity Inc. NERLYNX (neratinib) and FASLODEX (fulvestrant) - (FACT-4) HR-positive, HER2-negative breast cancer Phase 2 Trial Planned NERLYNX oral FASLODEX intramuscular Oncology